Publicacións nas que colabora con Ángel Fernández Trasancos (14)

2019

  1. Obesity-Related Genetic Determinants of Heart Failure Prognosis

    Cardiovascular Drugs and Therapy, Vol. 33, Núm. 4, pp. 415-424

2017

  1. Evolution and bad prognostic value of advanced glycation end products after acute heart failure: Relation with body composition

    Cardiovascular Diabetology, Vol. 16, Núm. 1

  2. Non classical Monocytes Levels, Increased by Subcutaneous Fat-Secretome, Are Associated with Less Rehospitalization after Heart Failure Admission

    Journal of Cardiovascular Translational Research, Vol. 10, Núm. 1, pp. 16-26

  3. Omentin treatment of epicardial fat improves its anti-inflammatory activity and paracrine benefit on smooth muscle cells

    Obesity, Vol. 25, Núm. 6, pp. 1042-1049

  4. Orosomucoid as prognosis factor associated with inflammation in acute or nutritional status in chronic heart failure

    International Journal of Cardiology, Vol. 228, pp. 488-494

2016

  1. Glucose and Inflammatory Cells Decrease Adiponectin in Epicardial Adipose Tissue Cells: Paracrine Consequences on Vascular Endothelium

    Journal of Cellular Physiology, Vol. 231, Núm. 5, pp. 1015-1023

  2. Sea cucumbers with an anti-inflammatory effect on endothelial cells and subcutaneous but not on epicardial adipose tissue

    Food and Function, Vol. 7, Núm. 2, pp. 953-963

2015

  1. Differential behaviour of epicardial adipose tissue-secretomes with high and low orosomucoid levels from patients with cardiovascular disease in H9C2 cells

    Molecular and Cellular Endocrinology, Vol. 416, pp. 77-87

  2. Orosomucoid secretion levels by epicardial adipose tissue as possible indicator of endothelial dysfunction in diabetes mellitus or inflammation in coronary artery disease

    Atherosclerosis, Vol. 235, Núm. 2, pp. 281-288

2014

  1. Adiponectin and p53 mRNA in epicardial and subcutaneous fat from heart failure patients

    European Journal of Clinical Investigation, Vol. 44, Núm. 1, pp. 29-37

  2. Differential Association of S100A9, an Inflammatory Marker, and p53, a Cell Cycle Marker, Expression with Epicardial Adipocyte Size in Patients with Cardiovascular Disease

    Inflammation, Vol. 37, Núm. 5, pp. 1504-1512

  3. Differential behavior between S100A9 and adiponectin in coronary artery disease. Plasma or epicardial fat

    Life Sciences, Vol. 100, Núm. 2, pp. 147-151

  4. Impaired Adipogenesis and Insulin Resistance in Epicardial Fat-Mesenchymal Cells From Patients With Cardiovascular Disease

    Journal of Cellular Physiology, Vol. 229, Núm. 11, pp. 1722-1730

2012

  1. Estudios del secretoma y proteoma de grasa epicárdica han determinado niveles de proteínas implicadas en el transporte de lípidos más bajos en pacientes con cardiopatía isquémica

    Proteómica: revista de la Sociedad Española de Proteómica, Núm. 8, pp. 106-106